Michael Hölzel

MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma

IL-17A-producing NKp44(−) group 3 innate lymphoid cells accumulate in Familial Adenomatous Polyposis duodenal tissue

High-salt diet induces immune-independent re-differentiation, metabolic shut down and cell cycle arrest of melanoma

<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer

CD4 ⁺ T cell immunity against cutaneous melanoma encompasses multifaceted MHC II–dependent responses

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial

Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma

Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization

Single-cell RNA sequencing identifies a population of human liver-type ILC1s

Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma

Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution

Re: First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma

<i>PD-L1</i> ( <i>CD274</i> ) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma

Spatial immunophenotypes of distant metastases and response to immune checkpoint inhibition.

Data from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

Data from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade

C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma

Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition

LAMP-Seq enables sensitive, multiplexed COVID-19 diagnostics using molecular barcoding

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells

Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis

Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin

RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas

In Vivo Labeling by CD73 Marks Multipotent Stromal Cells and Highlights Endothelial Heterogeneity in the Bone Marrow Niche

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy

MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy

Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression

Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis